ABSI Absci Corp
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1672688 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-47.2%
TTM net income YoY-9.7%
TTM EPS YoY13.2%
Revenue 3-yr CAGR-40.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,812.3%
Net margin-8,451.3%
FCF margin-7,562.7%
EBITDA margin-8,076.6%
Returns
ROE-58.6%
ROA-51.9%
ROIC (approx.)-53.3%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets8.7%
Debt / equity0.00x
Current ratio9.64x
Interest coverage-2,569.39x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue-4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.80M | $4.53M | $5.72M | $5.75M | $4.78M |
| R&D expense | $81.42M | $63.86M | $48.07M | $58.91M | $44.59M |
| SG&A expense | $35.06M | $36.17M | $37.83M | $40.55M | $28.78M |
| Operating income | -$120.32M | -$108.89M | -$115.52M | -$106.75M | -$75.24M |
| Interest expense | $209,000 | $565,000 | $1.01M | $972,000 | $3.43M |
| Pretax income | -$115.11M | -$103.04M | -$110.47M | -$105.36M | -$109.86M |
| Income tax | $69,000 | $70,000 | $100,000 | -$461,000 | -$8.90M |
| Net income | -$115.18M | -$103.11M | -$110.57M | -$104.90M | -$100.96M |
| EBITDA | -$108.58M | -$95.50M | -$101.52M | -$93.71M | -$68.58M |
| EPS (basic) | -0.84 | -0.94 | -1.20 | -1.15 | -2.08 |
| EPS (diluted) | -0.84 | -0.94 | -1.20 | -1.15 | -2.08 |
| Weighted avg. shares (diluted) | 136.78M | 110.24M | 92.03M | 90.85M | 49.69M |
| Balance sheet | |||||
| Cash & equivalents | $20.02M | $58.21M | $89.67M | $76.84M | $279.93M |
| Short-term investments | $124.27M | $71.21M | — | — | $0 |
| Receivables | — | $0 | $2.19M | — | — |
| Current assets | $149.57M | $133.83M | $120.58M | $186.86M | $273.08M |
| PP&E, net | $20.86M | $29.17M | $41.33M | $52.72M | $52.11M |
| Goodwill | — | — | $0 | $21.34M | $21.34M |
| Intangibles | $41.51M | $44.88M | $48.25M | $51.62M | $54.99M |
| Total assets | $216.30M | $213.61M | $217.30M | $321.01M | $426.19M |
| Current liabilities | $22.77M | $28.66M | $29.56M | $30.27M | $33.86M |
| Long-term debt | — | $3.99M | $7.92M | $10.93M | $3.52M |
| Total debt | — | $3.99M | $7.92M | $10.93M | $3.52M |
| Total liabilities | $26.85M | $34.48M | $41.12M | $46.59M | $60.09M |
| Shareholders' equity | $189.45M | $179.13M | $176.18M | $274.41M | $366.11M |
| Net debt | — | -$54.22M | -$81.75M | -$65.91M | -$276.40M |
| Shares outstanding | — | 115.36M | 93.09M | 92.41M | 92.65M |
| Cash flow statement | |||||
| Operating cash flow | -$92.92M | -$72.40M | -$64.64M | -$81.34M | -$60.60M |
| Capital expenditure | $1.11M | $404,000 | $860,000 | $16.18M | $38.05M |
| Free cash flow | -$94.03M | -$72.81M | -$65.50M | -$97.51M | -$98.64M |
| Investing cash flow | -$50.16M | -$41.58M | $81.94M | -$126.98M | -$67.38M |
| Financing cash flow | $105.95M | $82.53M | -$4.48M | $5.24M | $336.19M |
| Depreciation & amortization | $11.74M | $13.39M | $14.00M | $13.04M | $6.65M |
| Stock-based compensation | $18.32M | $19.45M | $11.42M | $12.54M | $10.61M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.